Phase II Study of Single Intraperitoneal Chemotherapy Followed by Systemic Chemotherapy for Gastric Cancer with Peritoneal Metastasis
- 574 Downloads
We conducted a phase II study involving a single administration of intraperitoneal chemotherapy with paclitaxel followed by sequential systemic chemotherapy with S-1+ paclitaxel for advanced gastric cancer patients with peritoneal metastasis.
Gastric cancer patients with peritoneal metastasis were enrolled. Paclitaxel (80 mg/m2) was administered intraperitoneally at staging laparoscopy. Within 7 days, patients received systemic chemotherapy with S-1 (80 mg/m2/day on days 1–14) plus paclitaxel (50 mg/m2 on days 1 and 8), followed by 7-days rest. The responders to this chemotherapy underwent second-look laparoscopy, and gastrectomy with D2 lymph node dissection was performed in patients when the disappearance of peritoneal metastasis had been confirmed. The primary endpoint of the study was overall survival rate.
Thirty-five patients were enrolled. All patients were confirmed as having localized peritoneal metastasis by staging laparoscopy. Eventually, gastrectomy was performed in 22 patients. The median survival time of the total patient population and those patients in which gastrectomy was performed was 21.3 and 29.8 months, respectively. The overall response rate was 65.7 % for all patients. The frequent grade 3/4 toxic effects included neutropenia and leukopenia.
Sequential intraperitoneal and intravenous paclitaxel plus S-1 was well tolerated in gastric cancer patients with peritoneal metastasis.
KeywordsGastric cancer Peritoneal metastasis Intraperitoneal chemotherapy Gastrectomy
The authors would like to express their appreciation to Dr. Harumasa Ohyanagi, Vice Board Director of the University of KinDAI Himeji, for his expert comments on the manuscript. We also wish to thank Ms. Fusako Kamada for her technical assistance.
The study was not supported by any grant.
- 7.Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H, Miyata Y, Taguchi T. Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol 2001; 12: 1133-1137.CrossRefPubMedGoogle Scholar
- 9.Mochiki E, Ohno T, Kamiyama Y, Aihara R, Haga N, Ojima H, Nakamura J, Ohsawa H, Nakabayashi T, Takeuchi K, Asao T, Kuwano H. Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer. Br J Cancer 2006; 95: 1642-1647.CrossRefPubMedGoogle Scholar
- 10.Imano M, Peng YF, Itoh T, Nishikawa M, Satou T, Yasyda A, Inoue K, Kato H, Shinkai M, Tsubaki M, Yasuda T, Imamoto H, Nishida S, Furukawa H, Takeyama Y, Okuno K, Shiozaki H. A Preliminary Study of Single Intraperitoneal Administration of Paclitaxel Followed by Sequential Systemic Chemotherapy with S-1 plus Paclitaxel for Advanced Gastric Cancer with Peritoneal Metastasis. Anticancer Res 2012; 32: 4071-4076.PubMedGoogle Scholar
- 11.Japanese Gastric Cancer A. Japanese Classification of Gastric Carcinoma - 2nd English Edition. Gastric Cancer 1998; 1: 10-24.Google Scholar
- 13.Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003; 21: 54-59.CrossRefPubMedGoogle Scholar